Patents by Inventor Douglas Behenna

Douglas Behenna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazopyridazines as modulators of IL-17
    Patent number: 12024524
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Grant
    Filed: April 7, 2023
    Date of Patent: July 2, 2024
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Steven Goldberg, David Kummer, John Keith, Craig Woods, Timothy Rhorer, Virginia M. Tanis, Connor Martin, Steven Meduna, Stefan McCarver, Alexander Valdes, Steven Loskot, Douglas Behenna, Alexander Rovira, Charlotte Deckhut, Xiaohua Xue
  • IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17
    Publication number: 20230357254
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: April 7, 2023
    Publication date: November 9, 2023
    Inventors: Steven GOLDBERG, David KUMMER, John KEITH, Craig WOODS, Timothy RHORER, Virginia M. TANIS, Connor MARTIN, Steven MEDUNA, Stefan McCARVER, Alexander VALDES, Steven LOSKOT, Douglas BEHENNA, Alexander ROVIRA, Charlotte DECKHUT, Xiaohua XUE
  • Imidazopyridazines as modulators of IL-17
    Patent number: 11702422
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: July 18, 2023
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Steven Goldberg, Timothy B. Rhorer, Connor Martin, Steven P. Meduna, Stefan McCarver, Alexander Valdes, Douglas Behenna, Xiaohua Xue, John Keith
  • Imidazopyridazines as modulators of IL-17
    Patent number: 11691979
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: July 4, 2023
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Steven Goldberg, Craig Woods, Timothy B. Rhorer, Connor Martin, Steven P. Meduna, Stefan McCarver, Alexander Valdes, Steven Loskot, Douglas Behenna, Alexander Raymond Rovira, Xiaohua Xue
  • IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17
    Publication number: 20230081548
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: January 14, 2022
    Publication date: March 16, 2023
    Inventors: Steven GOLDBERG, Craig WOODS, Timothy B. RHORER, Connor MARTIN, Steven P. MEDUNA, Stefan McCARVER, Alexander VALDES, Steven LOSKOT, Douglas BEHENNA, Xiaohua XUE
  • IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17
    Publication number: 20220402922
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: April 28, 2021
    Publication date: December 22, 2022
    Inventors: Steven GOLDBERG, David KUMMER, John KEITH, Craig WOODS, Timothy RHORER, Virginia M. TANIS, Connor MARTIN, Steven MEDUNA, Stefan McCARVER, Alexander VALDES, Steven LOSKOT, Douglas BEHENNA, Alexander ROVIRA, Charlotte DECKHUT, Xiaohua XUE
  • Enantioselective, catalytic allylation of ketones and olefins
    Publication number: 20060084820
    Abstract: Compounds containing a substituted or unsubstituted allyl group directly bound to a chiral carbon atom are prepared enantioselectively. Starting reactants are either chiral or achiral, and may or may not contain an attached allyloxycarbonyl group as a substituent. Chiral ligands are employed, along with transition metal catalysts. The methods of the invention are effective in providing enantioconvergent allylation of chiral molecules.
    Type: Application
    Filed: August 29, 2005
    Publication date: April 20, 2006
    Applicant: California Institute of Technology
    Inventors: Douglas Behenna, Brian Stoltz, Justin Mohr, Andrew Harned